{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T10:32:33Z","timestamp":1785148353702,"version":"3.55.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"DOI":"10.1007\/s10637-026-01630-2","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T03:20:33Z","timestamp":1783653633000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Characterizing the post-market safety profile of lazertinib: a pharmacovigilance study of the FDA Adverse Events Reporting System Database"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4080-3030","authenticated-orcid":false,"given":"Connor","family":"Frey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"issue":"12","key":"1630_CR1","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/S1470-2045(19)30504-2","volume":"20","author":"MJ Ahn","year":"2019","unstructured":"Ahn MJ, Han JY, Lee KH et al (2019) Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study. Lancet Oncol 20(12):1681\u20131690. https:\/\/doi.org\/10.1016\/S1470-2045(19)30504-2","journal-title":"Lancet Oncol"},{"issue":"6","key":"1630_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.70153","volume":"86","author":"CS Gawli","year":"2025","unstructured":"Gawli CS, Nagpure NR, Patil BR, Ochi N, Takigawa N, Patel HM (2025) Lazertinib: a cardio-safer alternative to osimertinib for epidermal growth factor receptor L858R\/T790M double-mutant tyrosine kinase resistant non-small cell lung cancer. Drug Dev Res 86(6):e70153. https:\/\/doi.org\/10.1002\/ddr.70153","journal-title":"Drug Dev Res"},{"issue":"16","key":"1630_CR3","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","volume":"391","author":"BC Cho","year":"2024","unstructured":"Cho BC, Lu S, Felip E et al (2024) Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC. N Engl J Med 391(16):1486\u20131498. https:\/\/doi.org\/10.1056\/NEJMoa2403614","journal-title":"N Engl J Med"},{"issue":"2","key":"1630_CR4","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s40264-018-0772-x","volume":"42","author":"RR Shah","year":"2019","unstructured":"Shah RR, Shah DR (2019) Safety and tolerability of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in oncology. Drug Saf 42(2):181\u2013198. https:\/\/doi.org\/10.1007\/s40264-018-0772-x","journal-title":"Drug Saf"},{"issue":"8","key":"1630_CR5","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1001\/jama.2019.11058","volume":"322","author":"KC Arbour","year":"2019","unstructured":"Arbour KC, Riely GJ (2019) Systemic therapy for locally advanced and metastatic non\u2013small cell lung cancer: a review. JAMA 322(8):764\u2013774. https:\/\/doi.org\/10.1001\/jama.2019.11058","journal-title":"JAMA"},{"key":"1630_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107509","volume":"190","author":"B Chul Cho","year":"2024","unstructured":"Chul Cho B, Han JY, Hyeong Lee K et al (2024) Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: long-term follow-up results from LASER201. Lung Cancer 190:107509. https:\/\/doi.org\/10.1016\/j.lungcan.2024.107509","journal-title":"Lung Cancer"},{"issue":"8","key":"1630_CR7","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.cllc.2025.08.007","volume":"26","author":"JC Yang","year":"2025","unstructured":"Yang JC, Ahn MJ, Kim JH et al (2025) Central nervous system outcomes of lazertinib treatment in EGFR-mutated advanced NSCLC: pooled analysis from LASER201 and LASER301. Clin Lung Cancer 26(8):642-650.e6. https:\/\/doi.org\/10.1016\/j.cllc.2025.08.007","journal-title":"Clin Lung Cancer"},{"key":"1630_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/pharma3040026","author":"C Frey","year":"2024","unstructured":"Frey C (2024) Cardiovascular adverse events associated with prostate cancer treatment: a disproportionality analysis from the Food and Drug Administration adverse event reporting system database. Pharmacoepidemiol Drug Saf. https:\/\/doi.org\/10.3390\/pharma3040026","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"1630_CR9","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jdermsci.2013.05.009","volume":"72","author":"D Nanba","year":"2013","unstructured":"Nanba D, Toki F, Barrandon Y, Higashiyama S (2013) Recent advances in the epidermal growth factor receptor\/ligand system biology on skin homeostasis and keratinocyte stem cell regulation. J Dermatol Sci 72(2):81\u201386. https:\/\/doi.org\/10.1016\/j.jdermsci.2013.05.009","journal-title":"J Dermatol Sci"},{"issue":"4","key":"1630_CR10","doi-asserted-by":"publisher","first-page":"e181","DOI":"10.1016\/S1470-2045(14)71133-7","volume":"16","author":"C Robert","year":"2015","unstructured":"Robert C, Sibaud V, Mateus C et al (2015) Nail toxicities induced by systemic anticancer treatments. Lancet Oncol 16(4):e181-189. https:\/\/doi.org\/10.1016\/S1470-2045(14)71133-7","journal-title":"Lancet Oncol"},{"issue":"10","key":"1630_CR11","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1001\/jamaoncol.2024.2640","volume":"10","author":"MH Hong","year":"2024","unstructured":"Hong MH, Choi YJ, Ahn HK et al (2024) Lazertinib in EGFR-variant non\u2013small cell lung cancer with CNS failure to prior EGFR tyrosine kinase inhibitors: a nonrandomized controlled trial. JAMA Oncol 10(10):1342\u20131351. https:\/\/doi.org\/10.1001\/jamaoncol.2024.2640","journal-title":"JAMA Oncol"},{"issue":"1","key":"1630_CR12","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1242\/jcs.182584","volume":"130","author":"JC Miguel","year":"2017","unstructured":"Miguel JC, Maxwell AA, Hsieh JJ et al (2017) Epidermal growth factor suppresses intestinal epithelial cell shedding through a MAPK-dependent pathway. J Cell Sci 130(1):90\u201396. https:\/\/doi.org\/10.1242\/jcs.182584","journal-title":"J Cell Sci"},{"key":"1630_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.118562","volume":"192","author":"J Ariyadamrongkwan","year":"2025","unstructured":"Ariyadamrongkwan J, Muanprasat C (2025) Pathophysiological mechanisms underlying diarrhea across generations of EGFR-TKIs: the role of ERBB signaling and potential therapies. Biomed Pharmacother Biomedecine Pharmacother 192:118562. https:\/\/doi.org\/10.1016\/j.biopha.2025.118562","journal-title":"Biomed Pharmacother Biomedecine Pharmacother"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-026-01630-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-026-01630-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-026-01630-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T16:02:28Z","timestamp":1783699348000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-026-01630-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":13,"alternative-id":["1630"],"URL":"https:\/\/doi.org\/10.1007\/s10637-026-01630-2","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"assertion":[{"value":"22 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval and patient consent were not required as the U.S. FDA previously collected all data utilized in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing\u00a0interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}